Podcasts about neuromyelitis

Bei Frauen mit MS fördern eine stabile Erkrankung und kluge Therapieentscheidungen eine sichere Schwangerschaft und Stillzeit. Alle Fragen und Antworten zum Nachlesen gibt es auf meinem Blog: https://ms-perspektive.de/281-celia-oreja-guevara Prof. Celia Oreja-Guevara berät einmal pro Woche Frauen mit Multipler Sklerose und Kinderwunsch in der Universitätsklinik San Carlos in Madrid. Sie findet es am besten wenn die MS seit zwei Jahren unter Kontrolle ist. Dann stehen die Chancen auf eine entspannte Schwangerschaft sehr gut. Da Frauen mit MS bei der Geburt im Durchschnitt etwas älter sind, spielt die künstliche Befruchtung eine Rolle. Empfehlenswert ist die etwas teurere In-vitro-Variante, da sie höhere Erfolgschancen hat und Paaren Zeit und Enttäuschungen erspart bleiben. Generell hat sich gezeigt, dass eine Mutterschaft den langfristigen Verlauf der Erkrankung kaum beeinflusst und diesem für viele Menschen wichtigen Teil des Lebensglücks nichts im Wege steht. Durch moderne, effektive Therapien sind selbst hochaktive Verläufe sehr gut zu kontrollieren. Diejenigen, die stillen möchten, können dies tun. Dennoch sollte die Gesundheit immer an erster Stelle stehen, und wenn es schwierig oder sehr zeitaufwendig wird, sei es aus therapeutischen oder anderen Gründen, kann man ohne schlechtes Gewissen auf Ersatzmilch zurückgreifen. Wichtiger ist es, Schüben und möglichen Spätfolgen vorzubeugen, als um jeden Preis zu stillen. Erfahre mehr über die verschiedenen Themen rund um Schwangerschaft, Stillzeit und Immuntherapie für Frauen mit MS. Das Interview wurde ursprünglich in englisch für den internationalen Podcast entführt und ist eine Übersetzung. Inhaltsübersicht Einleitung - Wer ist Prof. Celia Oreja-Guevara? Allgemeine Informationen über den Kinderwunsch bei MS Spezielle Informationen zu Schwangerschaft und Geburt bei MS Stillen bei Multipler Sklerose Verabschiedung Einleitung - Wer ist Prof. Celia Oreja-Guevara? Ich bin Celia Oreja-Guevara, stellvertretende Vorsitzende der Neurologie und Leiterin des Multiple-Sklerose-Zentrums am Universitätskrankenhaus San Carlos in Madrid, Spanien. Ich bin Professorin für Neurologie an der Universität Complutense in Madrid. Nach meinem Medizinstudium an der Universität Madrid habe ich meine Doktorarbeit in Neuroimmunologie am Max-Planck-Institut für Neurobiologie in München abgeschlossen. Anschließend absolvierte ich eine Facharztausbildung in der Neurologischen Abteilung der Universität Bochum, gefolgt von einem einjährigen Stipendium für Neurobildgebung am Universitätsklinikum San Raffaele in Mailand. Seitdem hatte ich verschiedene Positionen inne, darunter leitende Neurologin an der Universität Düsseldorf, Deutschland, Leiterin der Neurologie am Hospital de Fuenlabrada und Vorsitzender des Multiple-Sklerose-Zentrums am Universitätsklinikum La Paz, beide in Madrid, Spanien. Ich bin Co-Vorsitzender des Wissenschaftlichen Gremiums für Multiple Sklerose der Europäischen Akademie für Neurologie. Meine Forschungsschwerpunkte sind klinische und bildgebende Zusammenhänge bei MS, Familienplanung, der Einsatz der optischen Kohärenztomographie in der symptomatischen Therapie, Neuromyelitis optica (NMO) und die Bewertung neuer Medikamente zur Behandlung von MS und NMO. Meine Hobbys sind Technik, ich kaufe Gadgets, repariere Computer, besuche Technikausstellungen … Außerdem reise ich gerne überall hin und schaue mir gerne Comedy und Liebesfilme an. Gibt es noch etwas, das du den Zuhörern mitteilen möchtest? Ja, gern. Für Patientinnen mit Multipler Sklerose ist eine Schwangerschaft mit den richtigen Vorbereitungen absolut möglich. Daher ist eine gründliche Familienplanung unerlässlich, um sowohl die Krankheit als auch die Schwangerschaft effektiv zu bewältigen und die Gesundheit von Mutter und Kind zu schützen. Wie und wo können Interessierte deinen Forschungsaktivitäten folgen? Twitter LinkedIn PubMed   Vielen Dank für die positiven Einblicke in das Thema Schwangerschaft und Stillzeit bei MS. Bis bald und mach das Beste aus Deinem Leben, Nele Mehr Informationen und positive Gedanken erhältst Du in meinem kostenlosen Newsletter. Hier findest Du eine Übersicht zu allen bisherigen Podcastfolgen.

E435 Alex Brito has Neuromyelitis optica spectrum disorder (NMOSD), a rare condition that targets the central nervous system. It can cause vision loss, chronic pain, and paralysis. Despite challenges—including an initial misdiagnosis, blindness and temporary paralysis, Alex helps others with disabilities and teaches adaptive technology to those with vision loss. She's also the first blind […]

In this week's podcast, Neurology Today's editor-in-chief highlights articles on the potential of a new blood biomarker for ALS, a PACP-targeted migraine therapy, and a real-world review of data on eculizumab for neuromyelitis optica spectrum disorder. This Podcast is being Sponsored by LocumTenens.com

Misdiagnosing multiple sclerosis (MS) is not uncommon. Neuromyelitis optica spectrum disorder (NMOSD) and myelin oligodendrocyte glycoprotein antibody disorder (MOGAD) can have clinical manifestations similar to MS. In this two-part episode, host Brett Drummond of MSTranslate speaks with Prof. Sara Mariotto of the University of Verona in Italy and Prof. Kazuo Fujihara of Fukushima Medical University in Japan about the latest research on the pathogenesis of these diseases, diagnostic criteria, potential treatment approaches, and any learnings that may be translated to MS.  

Misdiagnosing multiple sclerosis (MS) is not uncommon. Neuromyelitis optica spectrum disorder (NMOSD) and myelin oligodendrocyte glycoprotein antibody disorder (MOGAD) can have clinical manifestations similar to MS. In this two-part episode, host Brett Drummond of MSTranslate speaks with Prof. Sara Mariotto of the University of Verona in Italy and Prof. Kazuo Fujihara of Fukushima Medical University in Japan about the latest research on the pathogenesis of these diseases, diagnostic criteria, potential treatment approaches, and any learnings that may be translated to MS.

Dramatisch: Sehkraftverlust und Lähmungen in 1-2 Tagen „Eine rasche Visusminderung bis hin zum Visusverlust, also eine sehr ausgeprägte Einschränkung der Sehkraft, die auch nicht ganz selten beide Augen betrifft, ist letztlich etwas sehr dramatisches“, so schildert der Neurologe Prof. Achim Berthele aus München das häufigste Symptom einer Neuromyelitis-optica-Spektrum-Erkrankung die abgekürzt auch als NMOSD bezeichnet wird. Sie wird durch einen Autoantikörper ausgelöst, der neben einer Entzündung der Sehnerven auch das Rückenmark befällt und dort zu verschiedensten neurologischen Ausfällen führt, die sich innerhalb von 1-2 Tagen entwickeln. „Die Schwere der Symptome ist das entscheidende Warnsymptom“, die sogenannte Red Flag, die Patientinnen und Patienten sollten möglichst schnell einer neurologischen Diagnostik zugeführt werden, so Prof. Berthele. Neben Visusminderung und Lähmungen sollte auch bei einem selten auftretenden unstillbaren Schluckauf an eine NMOSD gedacht werden. Wichtig: möglichst schnelle neurologische Diagnostik Eine sorgfältige neurologische Bewertung, Bildgebung und der Nachweis von Aquaporin-4-Antikörpern sichern die Diagnose. Eine NMOSD tritt überwiegend bei jungen Frauen in der dritten Lebensdekade auf und wird durch eine Immuntherapie behandelt. Dabei ist Schnelligkeit gefragt: „Man muss rasch sehr aktiv behandeln, um die Betroffenen vor bleibenden Schäden zu bewahren“, fasst Prof. Berthele zusammen. Dies ist die erste Folge einer dreiteiligen Podcast-Serie zur Neuromyelitis-optica-Spektrum-Erkrankung, die mit freundlicher Unterstützung von Horizon Therapeutics entstanden ist, die jetzt zu Amgen gehören. DEU-NP-0124-80007 Mehr Folgen zum Thema unter: medical-tribune.de/o-ton-allgemeinmedizin

Sumaira Ahmed is a force! Upon being diagnosed with a rare neuroimmune condition (Neuromyelitis optica spectrum disorder/ NMOSD, whose symptoms can include vision loss, paralysis, and weakness), Sumaira couldn't find the community she needed, so she went right ahead and launched a foundation (two months later!) to create that support for herself and patients around the world. The Sumaira Foundation has since advocated for patients, funded disease research, increased NMO awareness globally and truly been a game changer in the field. Hear how this young dancer and Bollywood aspirant (who was crowned the first Miss Bangladesh-USA) turned into a fearless non-profit leader and champion for patients suffering from this rare disease.Join me with the wonderful Sumaira - now on your favorite podcast app, Spotify or iTunes and please please take a second to rate us wherever you're listening so the voices of these inspiring women can be heard all over the world!SHOWNOTES FOR EPISODE 88:Read more about Sumaira's work at The Sumaira Foundation and connect with her and The Sumaira Foundation on InstagramInfinite Vision: How Aravind Became the World's Greatest Business Case for CompassionQuestions? Comments? Get in touch @theindianeditpodcast on Instagram ! Want to talk gardens? Follow me @readyourgardenSpecial thanks to Sudipta Biswas and the team @ Boon Castle / Flying Carpet Productions for audio post-production engineering!

Dr. Martin answers questions sent in by our listeners. Some of today's topics include: Neuromyelitis optica Absorption of nutrients Glomerulonephritis Phototherapy patches Shingles & skin treatment Creatine Healing of nerve damage Cannabinoids Phlegm in throat Iodine Celery salt  

2015 wurde bei Becky die Diagnose der Multiplen Sklerose (MS) gestellt. Rückblickend waren allerdings erste Symptome wie z.B. eine exzessive Tagesschläfrigkeit, unerklärliche Schmerzen, Myoklonien (rasche, unwillkürliche Muskelzuckungen), Parästhesien und Taubheitsgefühle und auch Augenbewegungsstörungen bereits seit 2009 vorhanden. Zum Zeitpunkt der Diagnose befand sich Becky in einer ziemlich stressigen Lebensphase: Die Aufnahme einer stellvertretenden Leitungsposition und eine parallel laufende Weiterbildung zur Diabetesberaterin/DDG. Wir sprechen über ihren ersten schweren Schub, die Therapie aus Kortisonstoßtherapien und Plasmapherese (Blutwäsche) und wie ihr Umfeld auf die Diagnose reagiert hat und welche Unterstützung sie durch ihre Freund*innen, Arbeitskolleg*innen und Familie erhält. Außerdem erklären wir euch im Video welche verschiedenen Verlaufsformen es bei der Multiplen Sklerose gibt, was genau ein MS-Schub ist und welche Empfehlungen Becky euch mit auf den Weg gibt, nachdem sie seit nun fast 8 Jahren mit der Diagnose MS und anderen Autoimmunerkrankungen lebt. Was waren eure ersten Symptome und wie habt ihr die Diagnose erlebt? Wir freuen uns auf den Austausch mit euch in den Kommentaren. Habt ihr Fragen, Themenwünsche oder benötigt Hilfestellung? Meldet euch gerne hier: E-Mail: neurologie@mediosapotheke.de Montag - Freitag: 8Uhr bis 17Uhr Telefon: (030) 257 620 58 350 Quellenangaben und weiterführende Links: Deutsche Hirnstiftung; Patientenleitlinie Multiple Sklerose, Version 1.5 https://register.awmf.org/assets/guidelines/030-050p_S2e_Multiplen-Sklerose_2022-05.pdf Hemmer B. et al., Diagnose und Therapie der Multiplen Sklerose, Neuromyelitis-optica-Spektrum-Erkrankungen und MOG-IgG-assoziierten Erkrankungen, S2k-Leitlinie, 2023, in: Deutsche Gesellschaft für Neurologie (Hrsg.), Leitlinien für Diagnostik und Therapie in der Neurologie. Online: www.dgn.org/leitlinien (Zuletzt abgerufen am 19.06.2023) https://www.amsel.de/multiple-sklerose/behandeln/therapie-eines-multiple-sklerose-schubs/kortison-stoss-therapie/ https://www.dmsg.de/multiple-sklerose/ms-behandeln/therapiesaeulen/schubtherapie Pendelnystagmus: https://www.amsel.de/multiple-sklerose/wasistms/ms-lexikon/nystagmus/ https://befunddolmetscher.de/nystagmus https://www.gesundheitsinformation.de/was-passiert-bei-einer-lumbalpunktion.html https://www.dmsg.de/multiple-sklerose/ms-behandeln/therapiesaeulen/schubtherapie https://www.dmsg.de/multiple-sklerose/ms-erforschen/grafiken-des-quartals/monats/berichte-zu-grafiken-des-quartals/monats/schubfoermiger-verlauf https://www.dmsg.de/multiple-sklerose/was-ist-ms https://www.amboss.com/de/wissen/Multiple_Sklerose/

Neuromyelitis-optica-Spektrum-Erkrankungen (NMOSD) sind seltene entzündliche Autoimmunerkrankungen des zentralen Nervensystems, die meist schubförmig verlaufen. Wie grenzen sich diese Erkrankungen von der Multiplen Sklerose (MS) ab und welche Rolle spielen Aquaporin-4-Antikörper (AQP4-AK) dabei? Was passiert bei einem Schub und warum ist es so wichtig weitere Schübe zu verhindern? Antworten auf diese Fragen gibt NMOSD-Expertin Frau Professorin Trebst in der aktuellen Podcast-Folge. Gast: Prof.in Dr. med. Corinna Trebst, Stellvertretende Direktorin der Klinik für Neurologie mit Klinischer Neurophysiologie, Medizinische Hochschule Hannover; Mitglied der Neuromyelitis optica Studiengruppe (NEMOS) Moderator: Prof. Dr. med. Martin Grond, Chefarzt der Neurologie im Kreisklinikum Siegen DE/UNB-N/0030

In this episode Dr. Daniel Correa speaks to the winner of Season 3 MasterChef and James Beard Award semi-finalist, Christine Ha, about her neuromyelitis optica (NMO) diagnosis that caused her to lose her vision. Christine shares how she has adapted and excelled as a chef despite the challenges that accompany an NMO diagnosis. Next, Dr. Correa talks with Dr. Fiona Costello, neurologist and professor of neurology at the University of Calgary and clinician scientist with the Hotchkiss Brain Institute. Dr. Costello discusses NMO, a rare inflammatory autoimmune disorder of the central nervous system, and how it is treated and managed for people who are diagnosed with this rare condition.   Additional Resources:  https://www.brainandlife.org/articles/when-cookbook-author-and-masterchef-winner-christine-ha-lost-her  https://www.brainandlife.org/disorders-a-z/disorders/neuromyelitis-optica   https://www.brainandlife.org/articles/neuromyelitis-optica-whats-in-a-name   https://www.brainandlife.org/the-magazine/online-exclusives/what-is-neuromyelitis-optica/   https://www.theblindgoat.com/   https://www.theblindcook.com/   Social Media:    Guest: Christine Ha @theblindcook (Twitter); Dr. Fiona Costello @FionaCostello5 (Twitter)  Hosts: Dr. Daniel Correa @neurodrcorrea; Dr. Audrey Nath @AudreyNathMDPhD 

Dr. Paul Crane discusses Neuromyelitis optica spectrum disorder, also known as NMOSD. This podcast is sponsored by argenx. Visit www.vyvgarthcp.com for more information.  

Neuromyelitis-optica-Spektrum-Erkrankungen, kurz NMOSD, gehen in der Regel mit irreversiblen, meist unvorhersagbaren Schüben einher. Was aber bedeuten diese Schubereignisse, physisch wie psychisch, für die Patienten? Was für Symptome treten auf, bzw. welche Folgen können entstehen? Was können Behandler tun, um die Patienten bestmöglich zu betreuen? Diesen und weiteren Fragen stellt sich Prof. Dr. med. Dr. rer. nat. Sven Meuth in diesem Podcast. Gast: Univ.-Prof. Dr. med. Dr. rer. nat. Sven Meuth, Direktor der Klinik für Neurologie im Uniklinikum Düsseldorf Moderator: Prof. Dr. med. Martin Grond, Chefarzt der Neurologie im Kreisklinikum Siegen DE/UNB-N/0013

Das klinische Erscheinungsbild der Neuromyelitis-optica-Spektrum-Erkankungen (NMOSD) ist dem der Multiplen Sklerose (MS) sehr ähnlich, sodass in etwa 30% der NMOSD-Patienten initial mit MS fehldiagnostiziert werden1,2. In diesem Podcast diskutieren Dr. Alexander Emmer und Prof. Martin Grond über die Gemeinsamkeiten und Unterschiede dieser neuroimmunologischen Erkrankungen und erklären, wie eine Fehldiagnose verhindert werden kann. Gast: Dr. med. Alexander Emmer, leitender Oberarzt der Neurologie am Universitätsklinikum Halle Moderator: Prof. Dr. med. Martin Grond, Chefarzt der Neurologie im Kreisklinikum Siegen DE/SOL-N/0165

Der Ausschuss für Humanarzneimittel (CHMP) der EMA hat im März und April 2021 sieben neue Wirkstoffe zur Zulassung empfohlen, u. a. für/gegen schwere atopische Dermatitis, Neuromyelitis optica Spektrumstörungen, Hypercholesterinämie, myeloische Leukämie, chronisch lymphatische Leukämie und follikulärem Lymphom. Außerdem wird es eine neue Option für MS-Patienten geben. Sami und Andi berichten, Link zum Blog auf esanum siehe hier: (C) esanum.de

Can you imagine losing your ability to see? At 20 years old, this became Christine Ha’s reality. Instead of losing faith or focusing on what she had lost, she used it as her inspiration to pursue her life’s passion: cooking. Christine joined the competitive cooking reality TV show Masterchef, hosted by notoriously hard-to-please celebrity chef Gordon Ramsay. Christine won MasterChef Season 3, has hosted her own show, opened her own restaurant, written a New York Times bestseller Recipes from my Home Kitchen and so much more. In a season of great uncertainty for many of us, Christine's story of resilience, courage and passion will speak to your soul. SHOW NOTES: As an only Christine struggled to balance embracing her American roots and her family’s heritage. Growing up as a first-generation Vietnamese-American, Christine struggled yet is now grateful for an enriched childhood. While losing her mom at 14, Christine maintained a strong connection to her mom’s culture by living with her grandparents + extended family. At 20, Christine began experiencing optic nerve inflammation, causing blurry vision and shifting her life’s perspective. Before being properly diagnosed with Neuromyelitis optica (NMO), Christine suffered from spinal cord inflammation leading to paralysis from the neck down. Learning to live with vision loss: For years, Christine was constantly adapting to gradual vision loss causing her to re-learn how to accomplish daily tasks. Building confidence: Leaning on her network of support + local resources for adapting to a later-in-life disability, Christine learned how to use public transportation, use a white cane and read Braille. Celebrate the small victories: Starting with a peanut butter and jelly sandwich, Christine took small steps to relearn her culinary skills, giving her courage to continue. With the encouragement of her husband and friends, Christine auditioned for MasterChef only anticipating it’d be material for her creative writing. Fake it until you make it. Try your best, and if you believe it then eventually you will get there. “In spite of my disability, I was able to compete with the best of them.” Second-guessing: While facing numerous disadvantages, Christine found not being able to see what her competitors were preparing as an advantage. As a female Asian-American in the male-dominated culinary field, Christine found her success on MasterChef gave her confidence + courage. During each grueling challenge, Christine expected the worst and hoped for the best. In the final round, shocked + exhausted, Christine moved Gordon Ramsey to tears and was crowned the winner. “I wouldn’t ask for my vision back because my life has gotten better. It’s taught me gumption and fearlessness. My life is fuller now because I reach for things that I love like writing and cooking which I would not have done. I would have lived a safe life.” The Blind Goat: a twist on her nickname “The Blind Cook” and being born the year of the goat, Christine’s first restaurant is a modern Vietnamese gastropub. Learn more here. Xin Chao: meaning “hello” in Vietnamese was opened during the pandemic features modern Vietnamese dishes. Learn more here. Despite losing between 50-80% of expected revenue during the pandemic, Christine maintains hope + faith. Advice to those facing struggles: “I don’t like saying ‘things will get better’ because it’s a promise I can’t hold. I’d tell them things can suck and while I don’t know exactly what it feels like to be in their shoes, I’ve had my own struggles. Surround yourself with the right support network + be willing to ask for help and you will find the strength to make it through.” CHRISTINE HA'S LIVE INSPIRED 7 1. What is the best book you’ve ever read? Angela's Ashes by Frank McCourt. 2. What is a characteristic or trait that you possessed as a child that you wish you still exhibited today? I was less concerned about others. 3. Your house is on fire, all living things and people are out. You have the opportunity to run in and grab one item. What would it be? My MacBook Air because it has all my photos and recipes. 4. You are sitting on a bench overlooking a gorgeous beach. You have the opportunity to have a long conversation with anyone living or dead. Who would it be? Mother Theresa and ask, “what’s life like on the other side?” 5. What is the best advice you’ve ever received? Believe in yourself. 6. What advice would you give your 20-year-old self? Don’t care about the superficial things. You need to find out who your true friends are. 7. It’s been said that all great people can have their lives summed up in one sentence. How do you want yours to read? Christine Ha led the best life and was the best person she could be in the time that she lived. *** Join our Live Inspired Together community, text PODCAST2021 to 314-207-5010. *** About our sponsor: Keeley Companies wholeheartedly believes that if you get the people right -the results will follow. They set themselves apart with a forward-thinking culture that empowers their people and fosters loyal partnerships. Keeley Companies are a proud sponsor, partner, and super fan of the Live Inspired Podcast. Learn more about Keeley Companies.

Neuromyelitis optica spectrum disorder (NMOSD) is a rare auto-immune that can often be confused with more common conditions, like multiple sclerosis. Ophthalmologist are often the first persons to see these patients but they may be unfamiliar with the symptoms of NMOSD and that can lead to delays in diagnosis.This CME module about suspecting and diagnosing managing patients with NMOSD during an ophthalmologic visit is hosted by Michael Levy, MD, PhD, Associate Neurologist at Massachusetts General Hospital and Prem Subramanian, MD, PhD, Professor of Ophthalmology at the University of Colorado Hospital. The CME is jointly provided by American Academy of CME, Inc. and CheckRare CE, Inc, and supported by an educational grant from Alexion Pharmaceuticals.To earn a CME credit, go to https://checkrare.com/learning-center/courses/

Michael Levy, MD, PhD, Associate Professor, Harvard Medical School summarizes key research on neuromyelitis optica spectrum disorder (NMOSD) presented at the American Academy of Neurology (AAN) 2020 annual meeting. To obtain CME credit, go to https://checkrare.com/learning/p-aan2020-nmosd-abstract-highlights-from-aan-2020/

Join the Dark (Humor) Side Sign Up For Our VERY Infrequent Newsletter Sign up with your email address to receive news and updates. Email Address Sign Up We respect your privacy. Thank you! LinksMore Than A Spoonie BlogYoung People With Chronic IllnessAudibleAdam Ruins EverythingUniqlo Bras and Bra TopsVictoria JacksonFavorite Podcasts SickBoyStuff You Missed in History ClassLoreJoe RoganDeal With ItMyths and History What is your disorder? *Neuromyelitis optica, depression, adrenal insufficiency. Nmo is similar to MSAt what age did your disorder become a daily issue? *4Who were you before your illness became debilitating? *A funny sarcastic independent little girlWhat would you do if you were not dealing with your invisible illness? *I would’ve been finishing high schoolWhat would you like people to know about your daily life? *Everything is exhausting.What would make living and moving in the world easier for you? *Better options to help relieve symptomsDo you have any life hacks? *Yes! 1. water bottles 2. towels dressing gown 3. homeschoolingWhat kind of support do you get from family or friends? *I Need a full-time carer...to make me food and everything because I’m in bed all the time. My friends also help by treating me normally but also getting it.Have you ever had someone not believe you have an invisible illness because of your appearance and if so are there any examples that stand out? *I can’t remember an example. But people are always very impressed thanks blind because I manage wellHow has your invisible illness affected your relationships? *I don’t get to spend very much time with my family. But it makes the time we do more valuable, the dynamics of my relationship with my parents and brother are very interesting. They each go above and beyond for me. But don’t see me as broken. They see me as me.Is there anything you are afraid to tell people in your life? *That I often blame/doubt myself. Sometimes I worry I’m not trying hard enough. I compare myself.Does the fact that your disease is invisible change how healthcare professionals treat you? *No. I’m very lucky to have had the same team since I was 4, when they didn't doubt me. But I imagine if I were to be newly diagnosed now they would suspect it’s for attention and stuff.What is your best coping mechanism? *PODCASTS! I love them sooooo much n it’s an effortless distraction. I listen to so many that I can’t catch up

1) Stroke risk stratification in acute dizziness presentations and 2) Topic of the month: Neuromyelitis optica. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Andy Southerland interviews Dr. Kevin Kerber about his paper on stroke risk stratification in acute dizziness presentations. Dr. Sarah Wesley is reading our e-Pearl of the week about focal cortical dysplasia. In the next part of the podcast Dr. Stacey Clardy interviews Dr. Jacqueline Palace about the topic of aquaporin-4 molecular mimicry/pathogenesis/research developments. The participants had nothing to disclose except Drs. Southerland, Kerber, Wesley, Clardy and Palace.Dr. Southerland serves as Podcast Deputy Editor for Neurology®; serves as Clinical Research Advisor for Totier Technologies, Inc.Dr. Kerber received funding for travel from Elsevier Inc. and the American Academy of Neurology; receives royalties from the publication of the book Clinical Neurophysiology of the Vestibular System, 4th edition; is a consultant for the American Academy of Neurology, University of California San Francisco (including work on a project funded by AstraZeneca), and Best Doctors, Inc.; receives research support from the NIH; received speaker honoraria from American Academy of Neurology and University of California San Francisco and loan repayment award from the NIH; reviewed legal records of Phil Pearsons, MD, JD and National Medical Consultants.Dr. Wesley serves on the editorial team for the Neurology® Resident and Fellow Section.Dr. Clardy receives research support from the Western Institute for Biomedical Research.Dr. Palace serves as on the scientific advisory board for Merck Serono, Bayer Schering Pharma, Biogen Idec, Teva Pharmaceutical Industries Ltd., Novartis Pharmaceuticals UK Ltd., Sanofi-aventis, Alexion; received support for attending ECTRIMS Merck Serono Novartis and Biogen Idec Talks at scientific meetings (majority have CME) Bayer Schering Pharma, Biogen Idec, Merck Serono, Medimmune; is a consultant for Ono Pharmaceuticals Ltd., Chugai Pharma Ltd., CI Consulting, Biogen Idec, GlaxoSmithKline, Alexion; serves on the speakers' bureau of Teva The CMSC, U. S.; receives research support from Bayer Schering Pharma, Merck Serono, Novartis Teva Pharmaceutical Industries Ltd., MS Society UK, Guthy Jackson Foundation and Department of Health Risk Sharing Scheme, Clinical Coordinator since 2002 Department of Health funding for a neuromyelitis optica service and a congenital myasthenia service; receives revenue from a patent from ISIS innovation Limited, a wholly-owned subsidiary of the University of Oxford, has filed a patent application (WO2013/117930 A2) to protect for the use of metabolomics as a method to diagnose and stage disease in multiple sclerosis.

1) Autoimmune post-herpes simplex encephalitis in adults and teenagers and 2) Topic of the month: Neuromyelitis optica. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Heather Harle interviews Dr. Josep Dalmau about his paper on autoimmune post-herpes simplex encephalitis in adults and teenagers. Dr. Sarah Wesley is reading our e-Pearl of the week about immunotherapy-responsive seizures. In the next part of the podcast Dr. Stacey Clardy interviews Dr. Dean Wingerchuk about the topic of new guidelines for neuromyelitis optica. The participants had nothing to disclose except Drs. Dalmau, Wesley, Clardy and Wingerchuk.Dr. Dalmau serves as an editorial board member of Neurology® and UptoDate; serves as Editor-in-Chief of Neurology® Neuroimmunology and Neuroimflammation; is a consultant for Advance Medical; receives royalties for the following patents: Patent Ma2 autoantibody test, Patent NMDAR autoantibody test, patent application for the use of GABA(B) receptor, DPPX and IgLON5 autoantibody tests; received license fee payments for DPPX and IgLON5 autoantibody tests from Euroimmun; receives research support from Euroimmun, ISCIII, and the NIH.Dr. Wesley serves on the editorial team for the Neurology® Resident and Fellow Section.Dr. Clardy receives research support from the Western Institute for Biomedical Research.Dr. Wingerchuk serves as an editorial advisory board member for Current Medical Research and Opinion and Drugs in Context; serves as an editorial board member for Journal of Clinical Apheresis; serves as Co-Editor-in-Chief of The Neurologist; served on the adjudication committee for therapeutic trial for MedImmune; is a consultant for Alexion and MedImmune; receives research support from Alexion, TerumoBCT and Guthy-Jackson Charitable Foundation.

1) Spectrum of cognition short of dementia and 2) Topic of the month: Neuromyelitis optica. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Jeff Burns interviews Dr. David Knopman about his paper on the spectrum of cognition short of dementia. Dr. Ted Burns is interviewing Dr. Terrence Cascino for our “What's Trending” feature of the week about what AAN is doing to combat the trend of physician burnout. In the next part of the podcast Dr. Stacey Clardy interviews Dr. Sean Pittock about the topic of neuromyelitis optica assay development, treatments and mimics, including MOG antibodies. The participants had nothing to disclose except Drs. Jeff Burns, Knopman, Burns, Cascino, Clardy and Pittock.Dr. Jeff Burns serves on the editorial board for Journal of Alzheimer's Disease; receives royalties for the publications of Early diagnosis and treatment of mild cognitive impairment and Dementia: An atlas of investigation and diagnosis; is a consultant for PRA International and receives research support from the NIH, Alzheimer's Drug Discovery Foundation, Elan, Janssen Pharmaceuticals Inc., Wyeth, Pfizer Inc, Novartis Pharmaceuticals Ltd, Danone, Avid Radiopharmaceuticals, Merck Serono and for clinical trials. Dr. Knopman served as Deputy Editor for Neurology®; serves on a Data Safety Monitoring Board for Lundbeck Pharmaceuticals and for the DIAN study; is an investigator in clinical trials sponsored by TauRX Pharmaceuticals, Lilly Pharmaceuticals and the Alzheimer's Disease Cooperative Study; serves as a consultant to the Bluefield Project to Cure Frontotemporal Dementia; and receives research support from the NIH.Dr. Ted Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with UCB, CSL Behring, Walgreens and Alexion Pharmaceuticals, Inc.Dr. Cascino serves as President for the American Academy of Neurology.Dr. Clardy receives research support from the Western Institute for Biomedical Research.Dr. Pittock receives research support from Alexion, Guthy Jackson Charitable Foundation and the NIH.

1) Neurology® Neuroimmunology & Neuroinflammation: Rituximab in treatment-resistant CIDP with antibodies against paranodal proteins and 2) Topic of the month: Neuromyelitis optica. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Kelly Gwathmey interviews Dr. Isabel Illa about her Neurology: Neuroimmunology & Neuroinflammation paper on rituximab in treatment-resistant CIDP with antibodies against paranodal proteins. Dr. Ted Burns is interviewing Dr. Murray Grossman for our “What's Trending” feature of the week about his paper on the classification of primary progressive aphasia and its variants. In the next part of the podcast Dr. Stacey Clardy interviews Dr. Jeff Bennett about the topic of latest developments in neuromyelitis optica using his antibody library. The participants had nothing to disclose except Drs. Illa, Burns, Grossman, Clardy and Bennett.Dr. Illa received a travel grant from Genzyme; serves as an editorial board member of Neurologia; holds a patent for Dysferlin detection in monocytes; has consulted for Grifols; received research support from Fondo de Investigaciones Sanitarias and ISCIII, Ministry of Health (Spain), Fundacion Gemio.Dr. Ted Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with UCB, CSL Behring, Walgreens and Alexion Pharmaceuticals, Inc.Dr. Grossman serves on the scientific advisory board for Forum; serves as an editorial board member of Neurology®, Journal of Neurolinguistics, Journal of Alzheimer's Disease; serves on the editorial advisory board for Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration; receives research support from Wyncote Foundation, ALS Association and the NIH; received travel funding for a site visit from Max-Planck Society.Dr. Clardy receives research support from the Western Institute for Biomedical Research.Dr. Bennett serves on the scientific advisory board for Apsara Therapeutics; serves as an editorial board member of Journal of Neuro-ophthalmology, Multiple Sclerosis Journal and Neurology® Neuroimmunology and Neuroimflammation; has patents for compositions and methods for the treatment of neuromyelitis optica and novel blocking monoclonal therapy for neuromyelitis optica; is a consultant for EMD-Serono, Questcor Pharmaceuticals, Alnaylam Pharmaceuticals, Medimmune, Abbvie, Novartis, Chugai Pharmaceuticals Co., Ltd., Genzyme Corporation, Genentech, Inc.; receives license fee payments from Aquaporumab; has rights for future royalty payments from Aquaporumab; holds stock options in Apsara Therapeutics; receives research support from Questcor Pharmaceuticals, Novartis, NIH and Guthy-Jackson Foundation.NO CME WILL BE OFFERED THIS WEEK.

Neuromyelitis optica (NMO) predominantly affects women, some in childbearing age, and requires early therapeutic intervention to prevent disabling relapses. We report an anti-AQP4 antibody-seropositive patient who became pregnant seven months after low-dose (100 mg) rituximab application. Pregnancy showed no complications, and low-dose rituximab restarted two days after delivery resulted in neurological stability for 24 months. Remarkably, her otherwise healthy newborn presented with anti-AQP4 antibody and reduced B lymphocyte counts in umbilical cord blood, which normalized three months later. Confirming and extending previous reports, our case suggests that low-dose rituximab might be compatible with pregnancy and prevent rebound NMO disease activity postpartum.

1) Neuromyelitis optica phenotype and 2) Topic of the month: Bedside Neuro-ophthalmology. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Nick Johnson with Dr. Jacqueline Palace about her paper on neuromyelitis optica phenotype. Dr. Stacey Clardy is reading our e-Pearl of the week about Duret hemorrhage. In the next part of the podcast Dr. Beau Bruce interviews Dr. Jonathan Trobe about bedside visual field examination. The participants had nothing to disclose except Drs. Palace, Clardy, and Bruce.Dr Palace serves on the scientific advisory board for Charcot Foundation, Biogen Idec, Merck Serono Ltd, Bayer Schering Pharma, Novartis Pharmaceuticals Uk Ltd, Teva Pharmaceutical Industries Ltd.; receives research support from the National MS Society, QIDIS, Oxford Health Services Research Committee, John Fell Research Fund, Merck Serono Ltd. and Bayer Schering Pharma and conference expenses from Novartis and Merck Serono Ltd. Dr. Clardy serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Bruce received research funding from the NIH.

1) Neuromyelitis optica and 2) Topic of the month: Historical interviews. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Pearce Korb interviews Drs. Claudia Lucchinetti and Bogdan Popescu about their paper on neuromyelitis optica unique area postrema lesions. In the next segment, Dr. Stacey Clardy is reading our e-Pearl of the week about striatal hand and foot. In the next part of the podcast Dr. Farrah Mateen interviews Dr. Bud Rowland as part of our month of historical interviews. Over the subsequent three weeks, Dr. Mateen will interview Drs. C. Miller Fisher, Peter Dyck and Jerome Posner. The participants had nothing to disclose except Drs. Lucchinetti, Clardy, Mateen and Rowland.Dr. Lucchinetti may accrue revenue for a patent re: aquaporin-4 associated antibodies for diagnosis of neuromyelitis optica; receives royalties from the publication of Blue Books of Neurology: Multiple Sclerosis 3 (Saunders Elsevier, 2010); and receives research support from the NIH, the Guthy Jackson Charitable Foundation (PI), and the National MS Society.Dr. Clardy serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Mateen served on the editorial team for the Neurology® Resident and Fellow Section and is supported by the 2010 Practice Research Grant from the American Academy of Neurology.Dr. Rowland serves as Ombudsman for Neurology; receives royalties from the publication of Merritt's Neurology (Lippincott Williams & Wilkins, 2005); and served as Editor-in-Chief of Neurology Today.

Es werden zwei Fälle von Neuromyelitis optica beschrieben, die jeweils eine hochgradige Erhöhung der Proteine im Liquor aufwiesen. Während ein Patient nach 6monatigem Krankheitsverlauf starb und pathologisch-anatomisch untersucht werden konnte, überlebte der andere Patient mit erheblichen Residuen. Dieser Fall zeichnete sich dadurch aus, daß deutlich erhöhte IgA- und IgM-Werte sowohl im Liquor als auch im Serum vorlagen. Es wird diskutiert, ob die gefundenen Liquorveränderungen möglicherweise eine Abgrenzung entsprechender Fälle gegenüber der multiplen Sklerose zulassen.